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ABSTRACT
ENVIRONMENTAL CHEMICALS POTENTIALLY INTERFERE WITH THYROID
HORMONE ACTION IN HUMAN TERM PLACENTA
FEBRUARY 2012
KATHERINE GEROMINI, B.S., UNIVERSITY OF MASSACHUSETTS AMHERST
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor R. Thomas Zoeller
Thyroid hormone is essential for normal brain development and recognition
of this has led to universal screening of newborns for thyroid function to ensure that
circulating levels of thyroid hormone are within a range known to be supportive of
normal growth and mental development. Environmental chemicals that interfere
with thyroid function are known to inhibit normal growth and mental development.
Work from our lab and from labs internationally demonstrates in animal systems
that some industrial chemicals such as PCBs, PBDEs, and others may interact with
the thyroid hormone receptor(s) in ways that are not predicted by changes in serum
thyroid hormone levels. Our work demonstrates that the enzyme CYP1A1 must
metabolize some individual PCB congeners before they can interact with the thyroid
receptor. In animals, this requirement appears to be manifested in part by a strong
correlation between CYP1A1 and TH target gene expression. Here we present that
this pattern extends to humans by demonstrating a correlation between increased
CYP1A1 mRNA and an abundance of thyroid hormone responsive gene mRNA.
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CHAPTER 1
INTRODUCTION

Thyroid Hormone Action and Disruption
Thyroid hormone (TH) is necessary for the proper functioning of the human
body, but temporally and spatially specific actions of thyroid hormones play
important roles in development. It is widely recognized that TH is necessary for
proper fetal neurodevelopment, with TH deficiencies being linked to lower cognitive
function. When hypothyroidism is untreated at birth, serious mental deficiencies
quickly develop, and recognition of this has led to a screening of all newborns for
thyroid function.[1]
The effects of thyroid hormone within the adult human body and the
developing fetus are controlled by a complex and multifaceted system. Serum levels
regulate the production of the thyroid hormones triiodothyronine (T3) and
thyroxine (T4). Transporters control the movement of these hormones into specific
tissues, where they interact with the thyroid receptor (TR), which binds to the
thyroid response element (TRE) and induces or represses gene transcription.
Thyroxine-binding globulin binds T4 in serum, creating a reservoir of hormone in
circulation. The amount of deiodinases (e.g. D2, D3) also plays a role in the level of
thyroid hormones in different tissues, activating TH by converting T4 to the thyroid
receptor activator T3, or deactivating TH by converting it to an unusable form. The
complexity of thyroid hormone signaling, as well as the mechanisms of chemical
disruption are fully reviewed by Zoeller (2010)[2]. Because thyroid hormone
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signaling is so complex, it should be expected then that any chemical disrupting
some point in this system would have a complex pattern of effects.
One such group of chemicals that have been linked to altered levels of TH is
polychlorinated biphenyls (PCBs). PCBs could affect TH signaling by reducing serum
TH levels, interfering with the TR, or both.

PCBs Disrupt Thyroid Hormone Action in a Way That Is Inconsistent with
Hypothyroidism
PCBs are persistent environmental pollutants. Once used in industry for a
variety of purposes, production of these chemicals was banned in the 1970s. Despite
this, they remain ubiquitous, unavoidable contaminants in the environment and in
the human population[3]. PCBs and their hydroxylated metabolites (OH-PCBs) are
present in cord blood in concentrations that are predicted by maternal exposure[4],
indicating the fetus is also exposed to these chemicals during development.
PCBs are composed of two linked benzene rings with varying degrees and
placement of chlorination. Because of the differences in structures among these
individual congeners, they can have different biological effects[5]. Study of these
effects is complicated because commercial mixtures of PCBs are composed of
different congeners at varying ratios of concentration. Further, the ratios found in
the environment and in the human body are different from those of commercial
mixtures. Little research has focused on how mixtures of these chemicals are
interacting in the human body[6, 7].
In different mixtures, PCB congeners could interact to have different effects.
Congeners with similar actions could have additive effects while congeners with
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different actions may together form new patterns of disruption. Gauger et al. (2007)
have shown that mixtures of PCBs can cause an increase in TH responsive genes, but
when individual congeners (shown in Figure 1) are tested alone this effect is not
seen[8]. What chemical properties then of different PCB congeners could interact to
create this?

Figure 1. Representative examples of PCB congeners used in the Gauger et al.
2007 experiment. (A) Non-ortho PCB congeners, “dioxin-like”: 3,3’,4,4’tetrachlorobiphenyl (PCB 77) and 3,3’,4,4’,5-pentachlorobiphenyl (PCB 126).
(B) Mono-ortho PCB congeners: 2,3,3’,4,4’-pentachlorobiphenyl (PCB 105) and
2,3’,4,4’,5-pentachlorobiphenyl (PCB 118). (C) Di-ortho PCB congeners:
2,2’,3,4,4’,5’-hexachlorobiphenyl (PCB 138) and 2,2’,4,4’,5,5’hexachlorobiphenyl (PCB 153).[8]
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Congeners can be coplanar or non-coplanar, depending upon the placement
of chlorine. The coplanar PCBs, such as PCB 126, have dioxin-like effects: that is,
they activate the arylhydrocarbon receptor (AhR) and induce transcription of the
gene encoding the phase-I metabolic enzyme cytochrome P4501A1 (CYP1A1)[6].
The AhR is expressed in many fetal tissues as well as being highly expressed
in the human placenta. Areas of higher expression in the fetus include the lung and
liver, while the brain shows lower expression levels.[9]
Non-coplanar PCBs are not dioxin-like, but have other biological actions[6].
Results of dual-luciferase assays by Gauger et al. (2007) show that CYP1A1
induction and activity is necessary for specific non-coplanar, mono-orthosubstituted, PCBs 105 and 118 to drive thyroid receptor (TR) activation[8].

Figure 2. Proposed model for thyroid receptor activation by CYP1A1
metabolism of non-coplanar PCBs. The AhR is activated by coplanar PCBs or
other chemicals, inducing the expression of CYP1A1. The CYP1A1 enzyme
metabolizes non-coplanar, mono-ortho-substituted PCBs into their 4-hydroxy
metabolites. These hydroxylated forms interact with the thyroid receptor and
cause the transcription or regulation of thyroid hormone responsive
genes.[10]
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The following model has been proposed: that CYP1A1 metabolizes noncoplanar, mono-ortho-substituted PCBs, such as 105 and 118, into their 4-hydroxy
metabolite forms [e.g. 4-hydroxy-2,3,3′,4′,5-pentachlorobiphenyl (4-OHPCB107)[11]] and that these metabolites, which have similar chemical structure to
thyroid hormone, interact with the TR[12](Figure 2). This two-step process, in
which CYP1A1 mRNA expression is positively correlated with the expression of
genes regulated by thyroid hormone, provides us with a prediction to test this
action in other systems.
To test this hypothesis in vivo Giera et al. (2011) treated timed-pregnant rats
with various PCB mixtures and observed the gene expression in tissues of the pups
(i.e. liver, heart, pituitary). PCBs 105 and 118 induced the thyroid hormone
responsive genes Spot 14 and malic enzyme in liver, where the AhR is highly
expressed, only in the presence of the dioxin-like PCB 126. This addition of PCB 126
also corresponds to an increase of CYP1A1 mRNA, consistent with our hypothesis
that CYP1A1 is necessary to create metabolites which in turn cause induction of TH
responsive genes.
PCB exposure displayed different effects in different tissues. Mixtures
containing PCB 126 were able to cause an increase in CYP1A1 mRNA to a lesser
extent in pituitary, and yet there was no corresponding decrease in the thyroid
hormone inhibited gene, TSHβ, mRNA. Despite the pups given mixtures containing
PCB 126 still showing the decrease in T3 and T4, the tissue mRNA response was not
consistent with the positive control for hypothyroidism. It was concluded that,
within these tissues, CYP1A1 was not highly expressed enough to metabolize PCB
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congeners and cause a change in TH signaling. This clearly underlines that a
mixture of chemicals, as well as having unanticipated interactions, can have
paradoxical tissue and serum specific effects[10].

Maternal Thyroid Hormone and Role of the Placenta
The next question this raises is whether this metabolism observed in vitro
and in vivo can create metabolites in humans that can interact with the TR and cause
gene expression changes. Placenta was an obvious choice for examination; it is
easily collected after birth from live healthy donors and it plays an important role in
thyroid hormone delivery to the fetus[13].
Until relatively recently, it was believed that the placenta blocked the
transfer of thyroid hormone from the mother to the fetus. Deiodinases D2 and D3,
enzymes that inactivate thyroid hormone, are indeed present at high levels in the in
the placenta[14]. However, the fact that permanent developmental effects of
congenital hypothyroidism can be almost completely prevented by immediate T4
treatment after birth indicated that the developing fetus is protected by the mothers
T4 production. By treating pregnant rats with the antithyroid drug methimazole and
then rescuing with T4 injections, Calvo et al. were able to demonstrate in 1990 the
necessity of maternal T4 to the protection of pup brains from hypothyroidism[15].
Vulsma et al. proved the same protective effect in humans by demonstrating that
newborns completely lacking the genetic ability to synthesis T4 have detectable T4 in
cord blood at delivery, and develop the profile of hypothyroidism only after birth
[16].
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Because the thyroid hormone axis of the mother is linked to thyroid hormone
levels in the fetus and to its development, chemicals that disrupt TH signaling of the
mother affect the fetus as well. Not only is placenta one of the few tissues readily
available from healthy human donors, but endpoints observed in this tissue have
implications for both mother and child.
The TH responsive genes measured in this study were placental lactogen
(PL) and placental growth hormone (GH-V). In vitro studies have shown the TR to
interact with a thyroid response element of these genes[17]. Addition of T3, the
active form of TH, is observed in cell line studies to increase the transcription of
PL[18-20] and GH-V[18]. If the expression of these genes correlates with expression
of CYP1A1 mRNA, this is evidence that environmental chemical metabolites are
affecting thyroid responsive gene expression.
By collaboration with Dr. Larissa Takser (Sherbrooke University Hospital,
Quebec, Canada) we were provided with an opportunity to test this model in
humans. Dr. Takser provided us with a large sample of human placentas in order to
examine gene expression in this tissue.
These placentas were collected as part of an epidemiological study (named
GESTE) that recruited women in 2007 living in the Eastern Townships region of
Quebec, Canada during pregnancy. GESTE will follow these mother-infant pairs for
at least four years to assess the effects and magnitude of endocrine disruption on
maternal health and child development.
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Summary
Through our interdisciplinary collaboration, this research has the potential
to increase our understanding of the mechanisms of this example of xenobiotic
metabolism and eventually combine it with developmental endpoints. Being able to
assess the CYP1A1 and TH responsive gene mRNA levels on a large sample of human
placentas provides us with a unique and exciting opportunity to determine if the
proposed model of metabolism extends to humans.
We hypothesized that expression of CYP1A1 mRNA is positively correlated
with the abundance of mRNAs coding for TR genes in the human term placenta. This
would be consistent with AhR driven metabolism of certain chemicals to forms that
interact with the TR.
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CHAPTER 2
METHODS

Human Participation
Recruitment and sample collection took place in 2007 at Étienne-Lebel
Clinical Research (CRC) Center of the Sherbrooke University Hospital (CHUS)
(Quebec, Canada). The Human Research Ethics Committee of CHUS approved the
study protocol. Four hundred pregnant women were recruited for this study at their
first physician visit. Each participant gave informed consent. All women were at or
over the age of 18, less than twenty weeks pregnant, and had no known thyroid
disease.

Thyroid Function Analysis
TH levels were measured by the Takser lab at Sherbrooke University. Serum
free T4 (fT4) and total T4 were assessed in the mothers at recruitment (<20 weeks of
pregnancy) and at delivery, as well as in cord blood at delivery. fT4 was determined
by the electrochemiluminescent immunoassay system ADVIA Centaur (Bayer) and
total T4 by the Coat-A-Count radioimmunoassay (DPC Inc., Los Angeles, CA) at CHUS.

Placental Samples
Placentas were collected immediately upon delivery. Two placental lobes (i.e.
cotyledons), morphological units of the placenta, were sampled from the center of
the maternal side of each placenta (Figure 3). Samples were immediately stored at 80°C. Of these samples, one cotyledon was cut in half on ice and sent, stored in dry
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ice, to our facility at the University of Massachusetts Amherst. 172 placental samples
were received for use in this study.

A

Figure 3. Cross-sectional diagram of the human term placenta. (A) Highlights
a cotyledon. Two such units were sampled during the course of this
experiment. This sample contains largely maternally derived tissue, however
some fetal tissue is also present.[21]
RNA Isolation and DNase Treatment
For each sample received, a piece of frozen placental tissue approximately
300mg in weight was disrupted and homogenized with a Bullet Blender (Next
Advance Inc., Averill Park, NY). Total RNA was isolated using TRIzol Reagent
(Invitrogen Corporation, Carlsbad, CA), according to the manufacturer’s
instructions. RNA was dissolved in DEPC treated water. Concentration of RNA was
determined with a NanoDrop 1000 spectrophotometer (Thermo Scientific,
Wilmington, DE).
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A subset of samples was tested for the presence of genomic DNA. With
contamination of genomic DNA in the samples confirmed, all RNA samples were
treated with DNase using the Applied Biosystems TURBO DNA-free procedure
(Applied Biosystems, Inc., Foster City, CA). Concentration of treated RNA was again
determined with the NanoDrop 1000.

Quantitative RT-PCR
One microgram of RNA from each sample was reverse transcribed using the
Applied Biosystems High Capacity cDNA Reverse Transcription Kit by the
manufacturer’s instructions.
Each quantitative PCR reaction was 10μL in volume and was comprised of
300nM forward and reverse primers each of the target gene (Table 1), nuclease free
water, 5μL FastStart Universal SYBR Green Master (ROX) (Roche Diagnostics Corp.,
Indianapolis, IN) and cDNA. Because of the low abundance of CYP1A1 transcripts in
placenta, it was necessary to use 4μg cDNA to obtain a significant signal in CYP1A1
PCR reactions. For all other reactions, 1μg cDNA was used.
Table 1. Quantitative RT-PCR Primers.
Gene
CYP1A1
PL[22]
GH-V[23]
Β-actin[24]
18S[25]

Forward Primer (5’3’)
GCTCAGCTCAGTACCTCAGCCAC
CATGACTCCCAGACCTCCTTC
AGAACCCCCAGACCTCCCT
CCTGGCACCCAGCACAAT
ACACGGACAGGATTGACAGA

Reverse Primer (5’3’)
GGTCTTGAGGCCCTGATTACCCAG
TGCGGAGCAGCTCTAGATTCT
TGCGGAGCAGCTCTAGGTTAG
GGGCCGGACTCGTCATAC
GGACATCTAAGGGCATCACAG

Quantitative PCR was performed using the Strategene Mx3000P real-time
PCR machine (Agilent Technologies, Inc., Santa Clara, CA). Samples were run in
duplicate for each gene. A calibrator pool was run in triplicate for each gene on each
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plate. The following thermal profile was used for all runs: one cycle of 10 min at
95°C; 40 cycles of 15 s at 95°C, 30 s at 60°C, and 15 s at 72°C; one cycle of 1 min at
95°C, 30 s 55°C, and 30 s at 95°C. Melting-curve analysis was preformed to identify
the creation of non-specific products, in which case all genes for the sample were
rerun on a new plate.
Relative mRNA levels were determined by the Pfaffl method[26]: the
difference between cycle threshold number, as calculated by the Mx3000P software,
for a target gene and the reference gene, β-actin, was compared between the sample
and a calibrator pool to obtain a relative fold change value.

Statistical Analysis
Statistical analysis was carried out using Prism 4 (GraphPad Software, La
Jolla, CA). Relative gene expression level data sets were tested for normality using
the D’Agostino-Pearson omnibus K2 normality test and log transformed if necessary
to be consistent with a Gaussian distribution. Pearson’s correlation test was used to
compare the relative levels of CYP1A1 transcripts and thyroid hormone gene target
transcripts. If a correlation was observed, the linear regression line was calculated.
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CHAPTER 3
RESULTS

CYP1A1 mRNA Expression Is Correlated with the Expression of mRNAs of TH
Responsive Genes

Figure 4. Correlation between CYP1A1 and PL relative mRNA levels. PL and
CYP1A1 show a weak but significant positive log-linear correlation [r2 =
0.3924(df = 136), P < 0.0001]. Data were log transformed for statistical
analysis.
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Figure 5. Correlation between CYP1A1 and GH-V relative mRNA levels. GH-V
and CYP1A1 show a weak but statistically significant positive log-linear
correlation (r2 = 0.3565(df = 136), P < 0.0001). Data were log transformed for
statistical analysis.
Expression of CYP1A1 mRNA showed a correlation with the TH responsive
genes PL and GH-V. PL mRNA was correlated with CYP1A1 mRNA (Figure 4), r2 =
0.3924(df = 136), P < 0.0001. GH-V mRNA was correlated with CYP1A1 mRNA
(Figure 5), r2 = 0.3565(df = 136), P < 0.0001. mRNA expression data was log
transformed to create a Gaussian distribution for statistical analysis.
As a control, the fold change for the reference gene 18S was also compared to
CYP1A1 (not shown). There was a significant but small correlation between CYP1A1
and 18S relative fold change, r2 = 0.09425(df = 136), P = 0.0002 (log transformed
data).
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Figure 6. Correlation between PL and GH-V relative mRNA levels. PL and GH-V
relative mRNA expression shows a high positive linear correlation (r2 =
0.8827(df = 170), P < 0.0001). Data were log transformed for statistical
analysis.
PL and GH-V showed a very strong correlation with each other (Figure 6), r2
= 0.8827(df = 170), P < 0.0001. This is expected, and consistent with other
observations of parallel increase in transcription of these genes[27].
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CYP1A1 mRNA Expression Is Not Correlated with Measures of Maternal T4 or
Cord Blood T4 Levels

Figure 7. CYP1A1 relative mRNA levels compared to measures of T4. There was
no correlation between CYP1A1 mRNA levels and maternal serum fT4 (A) [r2 =
0.0005026(df = 110), P = 0.8145] or total T4 (B) [r2 = 0.03176(df = 112), P =
0.0578] at delivery. There was no correlation between CYP1A1 mRNA levels
and cord blood fT4 (C) [r2 = 0.006778(df = 118), P = 0.3714] or total T4 (D) [r2
= 0.0001525(df = 118), P = 0.8935]. CYP1A1 data is log transformed for
statistical analysis.
The expression of CYP1A1 mRNA showed no correlation with measures of
circulating free and total T4 levels, when data sets were examined as a group (Figure
7). There was no correlation between CYP1A1 mRNA expression and maternal
serum levels of fT4 [r2 = 0.0005026(df = 110), P = 0.8145] or total T4 [r2 =
0.03176(df = 112), P = 0.0578]. Though the low P value for the correlation of total
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maternal T4 and CYP1A1 mRNA could be interpreted as statistically significant, the
r2 of nearly zero indicates that this is not a correlation of biological interest.
To further analyze these findings, the data was broken into quintiles by T4
levels (not shown). When examining maternal fT4 at delivery in this way, the fifth
quintile, representing the group with the highest levels of fT4, shows a distinct
positive correlation between relative levels of CYP1A1 mRNA and fT4 [r2 = 0.3527(df
= 20), P = 0.0036]. This effect was not observed in any of the lower quintiles of fT4.
When examining maternal serum total T4 at delivery by quintile, no
correlations were observed between CYP1A1 relative mRNA levels and total T4.
Neither were correlations observed between CYP1A1 relative mRNA levels and free
or total T4 of cord blood, when divided into quintiles.
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TH Responsive Gene Expression in the Placenta Is Not Predicted by Maternal
Serum T4 Levels

Figure 8. PL and GH-V relative mRNA levels compared to measures of maternal
T4. PL shows no correlation with maternal fT4 at delivery (A) [r2 =
0.0002523(df = 139), P = 0.8517] but a slight correlation with total T4 (B) [r2 =
0.03927(df = 141) P = 0.0177]. Likewise, GH-V shows no correlation with fT4
at delivery (C) [r2 = 0.00007266(df = 139), P = 0.9201] but a slight correlation
with total T4 (D) [r2 = 0.04484(df = 141), P = 0.0111]. Relative fold induction
data is log transformed for statistical analysis.
The relative mRNA levels of the thyroid hormone responsive genes were
compared to measures of maternal T4 (Figure 8). The expression of PL and GH-V
mRNAs showed no correlation with the maternal level of fT4 at delivery. However,
both genes (log transformed) showed a weak correlation with maternal serum total
T4 at delivery. PL: r2 = 0.03927(df = 141), P = 0.0177 and GH-V: r2 = 0.04484(df =
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142), P = 0.0111. Such a low r2, however, indicates this effect is unlikely to be
biologically significant.
No correlations were found between thyroid hormone responsive gene
expression and measures of T4 in cord blood (not shown).

CYP1A1 mRNA Expression Is Not Affected by the Smoking of Mothers

Figure 9. CYP1A1 mRNA in smoking versus and nonsmoking mothers. CYP1A1
data (log transformed for statistical analysis) was grouped based on mothers’
reporting of smoking or not during pregnancy. The two groups were
compared using the student’s t-test. There was no significant difference
between the means of the two groups [t = 0.5995(df = 107), P = 0.5501].

No difference in placental CYP1A1 mRNA expression was found when
mothers were grouped based on their reporting of smoking or not during pregnancy
(Figure 9), t = 0.5995 (df = 107), P = 0.5501. This statistic, however, was reported
for only a portion of participants, with only 14 participants reporting that they
smoked during pregnancy.
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CHAPTER 4
DISCUSSION
These findings lend support for the hypothesis that environmental chemicals
can act as TH if they are metabolized by CYP1A1. This hypothesis has been tested in
vitro and in an animal model, but the results reported here are the first indications
that this mechanism extends into humans.

CYP1A1 and Thyroid Responsive Gene Induction
To see differences in TH action, we examined two genes known to be induced
by T3 in placenta, PL and GH-V. The increase in mRNA levels of these genes was
predicted by an increase in CYP1A1 mRNA. These data support the model that PCB
metabolism by CYP1A1 can affect TH gene expression and capitulate observations in
vitro and in vivo. This is consistent with the notion that CYP1A1 creates metabolites
that act as TH agonists.
As a negative control, we also examined a characterized housekeeping gene
in placenta, 18S. This gene should not change expression as a response to thyroid
hormone receptor activation. The correlation between CYP1A1 and 18S in placenta
was comparatively smaller than the relationship between CYP1A1 and the target
genes mRNA, supporting the conclusion that this response is specific to thyroid
hormone receptor activation.
In 20% of samples we were not able to obtain a qRT-PCR signal for CYP1A1.
These samples were excluded from these comparisons; however, they represent an
interesting subset of samples that should be investigated. It is likely the lack of
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CYP1A1 signal represents no induction or a level of induction that is below our
ability to detect. It would be interesting to examine if low exposure or genetic
factors are the cause of the low CYP1A1 induction in these individuals.
An additional interesting set of data to examine would be how CYP1A1 singlenucleotide polymorphisms (SNPs) contribute to the observed correlation. CYP1A1
SNPs have effects on gene expression[28] and enzyme activity[29, 30] and also are
linked to an increased risk for a number of cancers[31-34].

T4 Levels and Gene Induction
Studies have shown that T3 increases transcription of PL and GH-V in in vitro
cell line systems. Though T3 levels account for much of the thyroid hormone action
in tissue, T4 levels provide a more accurate overview of signaling in the body. Since
T3 and T4 levels are indirectly related, we expected that we could predict serum T4
levels from the PL and GH-V mRNA levels.
We did not see any significant correlations between free or total T4 levels in
maternal serum, or in cord blood, and the induction of TH responsive genes. This
indicates a disconnection between hormone levels in serum and hormone action in
tissue. The next step then is to examine TH levels in the tissue samples themselves
to better understand how TH levels and gene expression are linked in placenta.
We also observed that CYP1A1 mRNA levels did not predict T4 levels. We
expected to see an effect on T4 related to this marker of PCB metabolism. In animal
models, PCB exposure and CYP1A1 induction was linked to an increase in TR
responsive genes mRNA[8, 10] that corresponded with a decrease in serum total T4.
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Previous human studies, however, by the Takser lab found only a correlation
between PCB exposure and T3 levels but not T4 levels[35]. Some studies now
indicate that OH-PCB levels, but not total PCB levels, are correlated with declining
fT4 levels[36].
These results indicate that T4 levels cannot predict gene expression in human
placenta. Combining this data with measures of chemical exposure, as well as
examining tissue TH levels, could provide a more accurate picture of chemical
metabolism and its effects on the thyroid hormone axis.

Smoking During Pregnancy
To examine how behavior can affect exposure we looked to see if individuals
who reported smoking had higher CYP1A1 mRNA levels, and therefore higher TH
responsive gene mRNA levels. No difference in CYP1A1 mRNA levels was found
between self-reported smoking and non-smoking during pregnancy. It is well
established that smoking increases levels of CYP1A1 mRNA in human termplacenta[37], as well as increases related enzymatic activity[38].
A great amount of variability of this effect between individuals, however, has
been reported and factors such as genetics and the extent and timing of smoking
during pregnancy have been proposed to cause this[37]. Further, this statistic was
reported for only 63% of participants, with only 14 individuals reporting to have
smoked during their pregnancy. It is likely that for an enlightening analysis more
data concerning this activity, such as examining chemical markers of smoking, is
necessary than a self-reported binary.
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CHAPTER 5
CONCLUSIONS
This test of the hypothesis that environmental chemicals can interfere with
thyroid hormone signaling clearly supports the proposed model of PCB metabolism
by CYP1A1. By observing the predicted effect of CYP1A1 on TH responsive genes, we
demonstrate that, within the human population, exposure to environmental
chemicals can cause a change in TH signaling.
Further, we could not predict this effect by looking at serum hormone levels.
This is not surprising, as this metabolism and disruption occurs on the level of the
tissue, and previous studies indicate these tissue effects are not uniform. To what
extent this affects the creation and circulation of TH remains to be seen.
This research also underlines that the study of chemicals in isolation cannot
provide the whole picture of the risk a chemical poses. An endocrine disruptor may
only have an effect after a series of other factors have occurred. In this model,
people with elevated levels of CYP1A1 for any reason (e.g. exposure to other dioxinlike chemicals, smoking) could be at increased risk. Interaction with other chemicals
must be considered.
Recognition of the fact that proper TH signaling is essential for healthy
human development has led to nearly universal screening of thyroid function at
birth. Yet this realization has not penetrated other areas of concern, such as how
signaling can be disrupted by the chemicals we put into our environment. Clearly we
need to discover new endpoints for assessing the power of chemicals to interfere
with thyroid hormone action.
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